Quick Facts

• Primary Use: Management of symptoms related to overactive bladder (OAB).
• Symptom Relief: Addresses urgency, urinary frequency, and urge urinary incontinence.

---

What Спазмекс Treats: Main Uses and Benefits

Спазмекс (Trospium chloride) is a medication utilized in the care of individuals experiencing symptoms associated with overactive bladder (OAB) syndrome. This condition involves involuntary contractions of the bladder muscle.

The medication is employed to provide relief for key symptoms of OAB. It may help in the management of an increased or frequent need to urinate, a sudden, compelling desire to pass urine (urgency), and the occurrence of uncontrolled urine leakage (urge urinary incontinence).

The use of this medication is associated with a reduction in the number of daily micturitions and a decrease in weekly episodes of urge incontinence in adults with OAB, contributing to the support of daily functioning.

The active ingredient, trospium chloride, is used in the management of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The prescribing healthcare provider determines if this treatment is appropriate for a patient's specific circumstances.

This medication is a component of a comprehensive treatment plan that may involve other non-pharmacological interventions.

Official Eligibility and Contraindications for Спазмекс (Trospium Chloride)

This medication is a muscarinic antagonist. Official regulatory documents define clear populations for whom its use is contraindicated or not recommended.

Populations that Must Not Use Спазмекс

Use is formally contraindicated for patients with the following conditions, due to the drug's mechanism of action and risk of serious complication:

• Urinary retention (difficulty or inability to empty the bladder).
• Gastric retention (a disorder that slows or stops the movement of food from the stomach).
• Uncontrolled narrow-angle glaucoma (a severe eye condition).
• Known hypersensitivity (allergy) to the active substance, trospium chloride, or any of the ingredients.

Restrictions and Special Consideration Groups

Use requires special consideration or is restricted for certain populations:

• Severe Renal Impairment: For patients with severe kidney disease (creatinine clearance less than 30 mL/minute), use of the extended-release formulation is not recommended due to significantly increased drug exposure. The immediate-release formulation may require a reduced dosage.
• Obstructive Disorders: Patients with clinically significant bladder outflow obstruction or gastrointestinal obstructive disorders should use the medicine with caution due to the risk of worsening retention.
• Other Conditions: Caution is also recommended for patients with controlled narrow-angle glaucoma, severe hepatic impairment (liver disease), and specific gastrointestinal conditions like ulcerative colitis, intestinal atony, and myasthenia gravis.

Regulatory documents establish this eligibility profile to mitigate the risk of anticholinergic side effects that can impede the body's natural functions of voiding urine and moving contents through the digestive tract.

Interactions with other medicines and products

The interaction profile for Спазмекс (Trospium Chloride) is defined by its method of clearance and potential for additive effects, according to regulatory labeling. The medicine is not expected to be involved in clinically relevant interactions via the major CYP450 enzyme systems.

Interacting Medicines and Mechanisms Co-administration with other Antimuscarinic Agents may lead to additive anticholinergic adverse effects. A pharmacokinetic interaction is officially documented with medicines that undergo active renal tubular secretion, as these may compete with Trospium Chloride for elimination pathways in the kidney. Use with Metformin (immediate-release tablets) has been shown to reduce the systemic exposure of Trospium Chloride. Conversely, co-administration with Digoxin results in no clinically significant change in the plasma concentration of either substance.

Timing and Population Constraints Administration of the Trospium Chloride tablet requires mandatory timing separation from food. The tablet must be taken at least one hour before a meal or on an empty stomach because food significantly reduces the drug's systemic exposure. For the extended-release formulation, alcohol must not be consumed within two hours of administration, as this substance may enhance certain central nervous system effects. Furthermore, patients with moderate renal impairment are expected to have increased systemic exposure, which heightens the risk of anticholinergic adverse reactions.

How Спазмекс Works

Спазмекс (trospium chloride) functions as a competitive antagonist at post-synaptic muscarinic cholinergic receptors, exhibiting affinity for both M2 and M3 subtypes, which are present on the smooth muscle cells of the bladder detrusor. This interaction prevents the binding and action of the endogenous neurotransmitter, acetylcholine (ACh), thereby interrupting the primary nerve impulse signaling chain that initiates smooth muscle contraction.

At the intracellular level, this antagonism uncouples the M3 receptor from its associated Gq protein signaling cascade. This action inhibits the subsequent activation of phospholipase C and the resulting release of intracellular calcium ions (Ca^2+), which are necessary for the smooth muscle cell to contract. The suppression of Ca^2+ release dampens the cellular excitability of the detrusor.

Physiologically, this molecular pathway leads to a reduction in detrusor muscle tone and a decrease in the frequency of involuntary muscle activation. The resulting smooth muscle relaxation influences the control of activity within the urinary tract and increases the volume the bladder accommodates prior to involuntary contraction.

How to Use Спазмекс (Trospium Chloride)

The administration of Trospium Chloride, the active ingredient in Спазмекс, follows specific parameters concerning dosage, frequency, and intake conditions. The medicine is taken via the oral route in the form of immediate-release film-coated tablets or extended-release capsules.

---

Standard Administration and Frequency

Dosage Form	Standard Adult Dosing	Frequency	Key Timing Constraint
Immediate-Release (IR) Tablets (20 mg)	20 mg per dose	Twice Daily (BID)	Must be taken on an empty stomach
Extended-Release (ER) Capsules (60 mg)	60 mg per dose	Once Daily (QD)	Must be taken on an empty stomach

---

Procedural Administration and Timing

The medicine is required to be taken on an empty stomach to ensure proper absorption, with administration occurring at least one hour before any meal. Both the tablets and capsules must be swallowed whole with water; the extended-release form, in particular, must not be crushed, chewed, or altered, as this disrupts the intended release of the medication. The necessity for continuing the treatment is subject to reassessment at regular clinical intervals, typically every three to six months.

---

Population-Specific Dosing Rules

Specific adjustments are utilized for certain patient groups. For adults with severe renal impairment (creatinine clearance < 30 mL/min), the IR dose is reduced to 20 mg once daily. In older adults (75 years), the dose of the IR form may be titrated down to 20 mg once daily based on individual response. The medicine is generally not recommended for pediatric patients under the ages of 12 or 18, depending on the specific product presentation.

Research evidence / Overview of studies for Спазмекс

Evidence for Use in Overactive Bladder (OAB) Symptoms

The primary clinical evidence for this medicine was gathered from short-term, randomized, double-blind, placebo-controlled trials (RCTs) which were used in the clinical evaluation of the medicine. These rigorous studies were conducted during periods of increased symptom activity in adults who experience OAB, a condition characterized by fluctuating or episodic manifestations of urgency and frequency.

The research examined the medicine's profile in various cohorts, including male and female patients with significant daily urinary frequency and urge urinary incontinence. The research was used in exploring how symptoms change over time when compared against an inactive substance (placebo). Findings from these pivotal studies described patterns observed where changes in daily urination frequency and urge urinary incontinence episodes were monitored and compared in the active treatment groups versus those who received placebo over the short observation period.

Outcomes Examined in Core Trials

Studies monitored several key measurement axes related to OAB symptoms. These included outcomes describing episodic or acute changes, such as the number of daily toilet voids and the number of urge urinary incontinence episodes, both tracked carefully by patients in bladder diaries.

Functional measures such as the volume of urine voided were among the outcomes examined. Research also explored changes in outcomes related to physical discomfort by measuring the severity of urgency using standardized scales. Research also explored changes in patient-reported outcomes describing perceived discomfort and overall quality of life related to bladder control. The evidence contributes to understanding the pattern of changes measured across all these functional and subjective axes.

Long-Term and Extended Follow-up Data

While the evidence from the core controlled trials is limited to the short-term, typically spanning 3 to 12 weeks, additional research has explored the long-term observation of symptom patterns. Open-label extension studies were conducted, monitoring responses over defined time intervals up to 9 months or 1 year.

Findings from these longer follow-up studies reported patterns where the initially measured changes were tracked during the extended period of observation. This evidence contributes to the broader evidence landscape by providing additional data on measurements collected during the extended duration, but it is important to note that these extended periods were often not blinded or placebo-controlled.

Evidence in Specific Patient Populations

The medicine was studied for use in specific populations, notably including older adults. Researchers explored whether there were any patterns related to cognitive function, which is an outcomes related to systemic or functional imbalance sometimes associated with this class of drug. The tests used to measure memory and thinking skills were included in the monitored outcomes, and research described the patterns observed during the study period.

Research has also examined the medicine in patients with conditions associated with acute or disruptive episodes, such as neurogenic OAB related to Parkinson's disease. These studies monitored changes in daily frequency and urgency over periods of up to a year, with findings describing how symptoms changed in these specific cohorts.

What is Still Uncertain About the Research

The quality of evidence for the main indication is based on the quantity of initial randomized, controlled data; however, several research limitation frames apply.

Firstly, the follow-up durations were limited in the core blinded trials, meaning limited information is available for long-term outcomes beyond a few months under controlled conditions. Secondly, comparative evidence is lacking from large-scale, head-to-head, blinded studies directly comparing this medicine against all other currently available medications in its class. Thirdly, while some research explored special populations, data for certain groups remain insufficient to draw broad conclusions. Findings describe group patterns, and research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Common questions about Спазмекс (FAQ)

---

Q: What is the active ingredient and the most common brand name for this medicine?

The active substance in this medication is Trospium Chloride. According to official regulatory documents, a common brand name under which the immediate-release tablet formulation is marketed in the U.S. is SANCTURA®.

---

Q: What is the recommended dose of the immediate-release tablet for adults?

Official prescribing information indicates that the dose frequently used for adults in clinical practice is 20 mg taken twice a day. Regulatory labeling notes that dose adjustments may be required for specific patient populations, such as those with severe kidney impairment or individuals who are older adults.

---

Q: How long does it typically take for Спазмекс to start working?

Studies and official information indicate that controlled clinical trials often monitored patient symptoms over observation periods, such as 12 weeks. Statistically significant changes in key symptoms were measured and compared to placebo during these periods. Regulatory documentation does not provide an exact time frame for when an individual patient can expect to feel the initial effects.

---

Q: What should I do if I miss a dose of my Trospium Chloride tablet?

Instructions for a missed dose generally state that if a dose is forgotten, it may be taken as soon as it is recalled before the next meal. If it is close to the time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is resumed. It is noted that a double dose should not be taken to make up for a missed one.

---

Q: Is Спазмекс safe to use during pregnancy or breastfeeding?

Regulatory documents include a cautionary statement that use during pregnancy may be considered only if the potential benefit warrants the potential risk to the fetus, as human studies are lacking. For breastfeeding, it is not known if the drug passes into human milk, so the decision requires considering the necessity of the drug for the mother and the potential risks to the infant.

How to Store and Dispose of Спазмекс?

The official requirements for storing this medicine are focused on protecting the tablets and ensuring safety.

Storage Requirements

Condition	Requirement (Official Label)
Temperature	Does not require any special storage conditions.
Container	Must be kept in the container it came in, tightly closed.
Protection	Store away from excess heat and moisture (e.g., do not store in the bathroom).
Stability	Do not use the tablets after the expiry date (EXP) stated on the carton and blister pack.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Official regulations require the proper disposal of expired or unused tablets. The medicine must not be discarded via household waste or by flushing it into the wastewater system. Patients are instructed to consult their pharmacist for advice on how to safely dispose of the medicine according to local environmental regulations.